Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PDL BioPharma (PDLI) and CytomX Therapeutics Inc (CTMX).
PDL BioPharma (PDLI)
In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma, with a price target of $3. The company’s shares closed yesterday at $2.87.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.6% and a 46.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
PDL BioPharma has an analyst consensus of Hold, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
CytomX Therapeutics Inc (CTMX)
In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on CytomX Therapeutics Inc. The company’s shares closed yesterday at $10.92, close to its 52-week low of $8.94.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 2.0% and a 40.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on CytomX Therapeutics Inc is a Strong Buy with an average price target of $21, a 92.3% upside from current levels. In a report issued on July 26, Mizuho Securities also reiterated a Buy rating on the stock with a $16 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
